The current invention provides the use compounds of Formula (I) which are JAK inhibitors, and as such for the treatment of JAK-1 mediated diseases such as atopic—and allergic dermatitis in young animals.
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A method of preparing a compound of Formula (I) or salt thereof, with reduced carboxylic acid by-product production.
A method of preparing a compound of Formula (I) or salt thereof, with reduced carboxylic acid by-product production.
C07C 269/06 - Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
C07C 211/27 - Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
C07C 211/40 - Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing only non-condensed rings
C07C 259/06 - Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
C07C 269/04 - Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups the nitrogen atom not being part of nitro or nitroso groups from amines with formation of carbamate groups
C07C 271/20 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
C07D 213/38 - Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
3.
A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OTIC INFECTIONS
Disclosed is a novel pharmaceutical composition for the treatment of car infections in an animal with a single dose administration comprising a gentamicin antibiotic, a posaconazole antifungal and a mometasone anti-inflammatory.
A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 47/06 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
transtranstrans)-2,2- dichloro-3-(3,5-dichlorophenyl)cyclopropane-1-carboxylic acid with a chiral base being either (1S,2R)-2- amino-1,2-diphenylethan-1-ol or (1R,2S)-2-amino-1,2-diphenylethan-1-ol in an organic solvent to form a suspension, (b) isolating a diastereoisomeric salt of the desired enantiomer and the chiral base from the suspension, and (c) optionally, treating the isolated diastereoisomeric salt with an acid to obtain the desired enantiomer of 2,2-dichloro-3-(3,5-dichlorophenyl)cyclopropane-1-carboxylic acid.
C07C 215/30 - Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings containing hydroxy groups and carbon atoms of six-membered aromatic rings bound to the same carbon atom of the carbon skeleton
5.
CARBOXAMIDE-4-QUINOLINE COMPOUNDS WITH ANTHELMINTIC ACTIVITY
The present invention provides novel carboxamide-4-quinoline compounds that can be used as medicaments, particularly in the treatment and prevention of diseases in animals caused by helminths.
The invention relates to the field of Aqua culture, especially to the farming of Tilapia, and more specifically the invention relates to a new type of bacterium of Streptococcus agalactiae serotype Ia (Sa Ia), which is much more pathogenic than Sa Ia isolates known so far, and can break through the protection provided by existing Sa Ia vaccines. In particular the invention relates to an Sa Ia bacterium of the new breakthrough type, as defined by a number of unique features, and as deposited at the CNCM in Paris. Further the invention regards preparations, compositions, and vaccines of the new Sa Ia bacterium, regards a diagnostic kit, and regards (medical) uses, and methods for the manufacture of the preparations, compositions, and vaccines of the new Sa Ia bacterium.
The present invention pertains to a novel rotavirus, especially an isolated virus, which is a member of the sub-species of porcine group B rotavirus (porcine RVB), causing diarrheal disease in pigs, to DNA fragments and corresponding proteins of the said virus, to vaccines on the basis of said virus, DNA and/or protein and to antibodies reactive with said virus and/or protein and diagnostic test kits for the detection of said virus.
The present invention provides a recombinant protein, and a recombinant vector expressing that protein, that can be used for the vaccination of seropositive avians, whereby the antibodies in the avian target are specific for an antigen comprised in that recombinant protein. By comprising in the recombinant protein also a domain that can bind to a cell surface protein on avian antigen presenting cells (APCs), the antigen is targeted to those APCs. It was found that this type of vaccine could safely overcome the negative effects of antibody interference, even after a single dose, even in very young avians, and even in the context of very high antibody levels.
An injection system for treatment of the human or animal body, comprising an injector (10) having at least one chamber (18) for accommodating a treatment fluid, the chamber (18) opening out into a nozzle (20) and being connected to a pressurizing system for pressurizing the fluid in the chamber such that a skinpenetrating jet (24) is ejected from the nozzle (20), wherein the system comprises at least one alternative administering device (26, 28) for administering the treatment fluid, and the nozzle (20) of the injector is integrated with an adapter (30) that is connectable to a mating adapter (32) of said at least one alternative administering device (26. 28).
The invention pertains to a method to produce a vaccine to protect a pig against a pathogenic infection with Streptococcus suis, the method comprising recombinantly expressing an IgM protease antigen in E. coli bacteria, subjecting the E. coli bacteria to a high pressure homogenisation operation at a pressure of at least 500 bar to induce lysis of the E. coli bacteria and release of the IgM protease antigen into the supernatant of the lysate, separating the supernatant from the pellet and mixing the supernatant comprising the IgM protease antigen with a pharmaceutically acceptable carrier to constitute the vaccine. The invention also pertains to a vaccine produced with this method.
The invention pertains to a method of culturing Lawsonia intracellularis bacteria, the method comprising a) infecting a first portion of McCoy cells with Lawsonia intracellularis bacteria, b) growing the first portion of infected McCoy cells in a first growth medium at a dissolved oxygen concentration less than 18% to arrive at a first culture of McCoy cells infected with Lawsonia intracellularis bacteria, c) determining the concentration of pyroptotic McCoy cells in the first culture of McCoy cells, d) combining a second portion of the first culture of McCoy cells with a second growth medium, and passing a third portion of the first culture to a third growth medium containing fresh McCoy cells, such that the third growth medium is inoculated with 0.01-0.25 pyroptotic McCoy cells per fresh McCoy cell, e) growing the McCoy cells in the second growth medium at a dissolved oxygen concentration less than 18% and growing the McCoy cells in the third growth medium at a dissolved oxygen concentration less than 18% to arrive respectively at a second culture of McCoy cells infected with Lawsonia intracellularis bacteria and a third culture of McCoy cells infected with Lawsonia intracellularis bacteria, f) harvesting the McCoy cells infected with Lawsonia intracellularis bacteria from the second culture of McCoy cells and determining the concentration of pyroptotic McCoy cells in the third culture, and g) performing steps d)-f) for the third culture, wherein the third culture serves as the first culture of McCoy cells.
The present invention provides a vaccine for feline leukemia virus and methods of making and using the vaccine alone, or in combinations with other protective agents.
The invention concerns a method of producing a foot and mouth disease virus (FMDV) virus-like particle (VLP) in a baculovirus expression system, the method comprising the steps of (i) infecting an insect cell with a baculovirus expression vector, (ii) culturing the insect cell in cell culture medium for 4 days or more post infection, (iii) separating the insect cells from the cell culture to obtain cell-free cell culture medium, and (iv) harvesting the FMDV VLP from the cell-free cell culture medium. The invention further relates to a vaccine for use in the protection of a subject against an infection with FMDV, the vaccine being obtainable by the method of the invention.
Erysipelothrix rhusiopathiaeErysipelothrix rhusiopathiaeErysipelothrix rhusiopathiae and an infection with porcine parvo virus, by injection of the first vaccine into the dermis of the pig.
The invention pertains to a vaccine comprising a non-replicating Leptospira immunogen, for use in prophylactically treating a pig against an infection with a Leptospira bacterium, by injection of the first vaccine into the dermis of the pig.
A device for administering a fluid is provided, with a cylinder, a piston, a piston rod, a receiving block (10), a nonreturn valve, a tensioning device, a ramp, a motor (12), a ramp track, a roller and a driver (50).
Erysipelothrix rhusiopathiaeErysipelothrix rhusiopathiaeErysipelothrix rhusiopathiae, an infection with porcine parvo virus and an infection with Leptospira bacterium, by associated separate injection of the first vaccine and the second vaccine into the dermis of the pig at a first and a second injection site of that pig respectively.
The present invention provides compositions for treating atopic dermatitis in canines that comprise a combination of fusion proteins that bind to canine Interleukin-4 with fusion proteins that bind to canine Interleukin-13. The fusion proteins that bind to canine Interleukin-4 comprise the extracellular domain of the canine Interleukin-4 receptor alpha, whereas the fusion proteins that bind to canine Interleukin-13 comprise the extracellular domain of the canine Interleukin-13 receptor alpha1. The compositions can further comprise a monoclonal antibody against canine IL-31 or against canine IL-31Rα. The present invention further relates to methods of treating canine atopic dermatitis using these compositions.
C07K 14/715 - ReceptorsCell surface antigensCell surface determinants for cytokinesReceptorsCell surface antigensCell surface determinants for lymphokinesReceptorsCell surface antigensCell surface determinants for interferons
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
19.
A VACCINE FOR PROTECTION AGAINST STREPTOCOCCUS SUIS OF VARIOUS SEROTYPES
The present invention pertains to a vaccine comprising in combination an IgM protease antigen of Streptococcus suis serotype 1, a Streptococcus suis bacterin serotype 9, sequence type 16, and a pharmaceutically acceptable carrier, The invention also pertains to a combination of an IgM protease antigen of Streptococcus suis serotype 1, and a Streptococcus suis bacterin serotype 9, sequence type 16, for use in a method to protect a pig against a pathogenic infection with Streptococcus suis and to a method for protecting pigs against a pathogenic infection with Streptococcus suis, by administering to the pigs an IgM protease antigen of Streptococcus suis serotype 1 and a Streptococcus suis bacterin serotype 9, sequence type 16.
42 - Scientific, technological and industrial services, research and design
Goods & Services
Providing a web site featuring technology that enables users to index, store, collect, and analyze information relating to poultry and flocks in electronic form
42 - Scientific, technological and industrial services, research and design
Goods & Services
Providing a web site featuring technology that enables users to index, store, collect, and analyze information relating to poultry and flocks in electronic form
22.
METHOD OF PRODUCING A FOOT AND MOUTH DISEASE VIRUS VIRUS-LIKE PARTICLE
The invention concerns a method of producing a foot and mouth disease virus (FMDV) virus-like particle (VLP) in a baculovirus expression system, the method comprising the steps of (i) infecting an insect cell with a baculovirus expression vector, (ii) culturing the insect cell in cell culture medium for 5 days or more post infection and (iii) harvesting the FMDV VLP from the cell culture medium. The invention further relates to a vaccine for use in the protection of a subject against an infection with FMDV, the vaccine being obtainable by the method of the invention.
The present invention provides a recombinant foot and mouth disease virus (FMDV) capsid precursor protein comprising a modified VP1 protein and optionally further comprising a modified VP4 protein. The invention further relates to an isolated nucleic acid molecule and an expression vector comprising the nucleic acid molecule for recombinant expression of the modified capsid precursor protein. In further aspects, the invention relates to a virus-like particle (VLP) obtained from the modified capsid precursor protein and a vaccine for use in the protection of a subject against an infection with FMDV produced from the VLP.
A method of preventing or treating a viral disease in an animal comprising administering to the animal a pharmaceutical composition comprising an antiviral nucleoside β-D-N(4)-hydroxycytidine (NHC) or a prodrug or salt thereof and a pharmaceutically acceptable carrier and wherein the viral disease is Porcine Reproductive and Respiratory Syndrome (PRRS), Bovine Respiratory Disease (BRD), Equine Influenza, Canine Distemper, Canine Respiratory Disease, Feline Infectious Peritonitis, Feline Viral Rhinotracheitis, or Feline Immunodeficiency.
A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
A system and method for predicting an illness, death or other abnormal condition of an animal is disclosed. A record for the animal including a monitored temperature time series of monitored temperature values that are indicative of a temperature of the animal over a given time period is provided. The monitored temperature time-series is a temperature pattern that includes two or more cycles that are defined by a distance between a given peak of the temperature pattern and a successive peak of the temperature pattern, or a distance between a given valley of the temperature pattern and a successive valley of the temperature pattern. The monitored temperature time-series is analyzed. Based on the analysis, a prediction of the illness, death or other abnormal condition of the animal within a given time duration of the given time period is made. A user of the system is notified of the prediction.
G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
26.
A VACCINE FOR PROTECTION AGAINST STREPTOCOCCUS SUIS OF VARIOUS SEROTYPES
The present invention pertains to a vaccine comprising in combination an IgM protease antigen of Streptococcus suis serotype (7), a Streptococcus suis bacterin serotype (9), sequence type (16), and a pharmaceutically acceptable carrier. The invention also pertains to a combination of an IgM protease antigen of Streptococcus suis serotype (7), and a Streptococcus suis bacterin serotype (9), sequence type (16), for use in a method to protect a pig against a pathogenic infection with Streptococcus suis and to a method for protecting pigs against a pathogenic infection with Streptococcus suis, by administering to the pigs an IgM protease antigen of Streptococcus suis serotype (7) and a Streptococcus suis bacterin serotype (9), sequence type (16).
The present invention pertains to a vaccine for protection against a pathogenic infection with Streptococcus suis, the vaccine comprising a whole IgM protease antigen of Streptococcus suis, the antigen comprising in its amino acid sequence less than four repeats, and a pharmaceutically acceptable carrier. The invention also pertains to this antigen for use in a method to protect a pig against such an infection, and to a method to protect such a pig.
The presently disclosed subject matter aims to a system and method directed to monitor the effect of a herpesvirus-based vaccine in an animal population. The system and method include a processing circuitry configured to: obtain one or more tissue samples of one or more respective animals of the animal population; sequence each of the tissue samples; calculate a score associated with the animal population based on the sequence of the tissue samples; compare the score to a benchmark determined from a dataset containing data associated with the effect of the herpesvirus-based vaccine in a plurality of animal populations; and, execute an action in response to the comparison to the benchmark.
A01K 45/00 - Other aviculture appliances, e.g. devices for determining whether a bird is about to lay
C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
32.
A VACCINE FOR PROTECTING A PREGNANT SWINE AGAINST AFRICAN SWINE FEVER
The invention pertains to a live attenuated African swine fever virus Georgia 2007 (ASFV-G) Δ9GL/ΔUK strain for use in a vaccine for protecting a pregnant swine against an infection with African swine fever virus (ASFV) by administering the vaccine comprising the live attenuated ASFV-G-Δ9GL/ΔUK strain to the pregnant swine.
Salmonid alphavirus (SAV) is an important pathogen affecting the aquaculture of Salmonid fish. Vaccines based on DNA plasmids expressing a SAV antigen have been described. However these are difficult to prepare at large scale and at the desired quality level. Also, they are commonly administered at relatively high amounts of plasmid per animal dose. This makes such DNA vaccines less affordable for this market. The invention discloses an improved plasmid that allows effective use as a DNA vaccine against SAV, but at a much reduced amount of DNA per dose. The plasmid contains a gene encoding a bacterial enzyme: Fab.
C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
A method for counting bird parasites (22) by capturing an image of a target area (20) that the parasites are expected to cross, and using image recognition techniques for discerning the parasites, characterized in that the target area (20) is a portion of a substrate (12) on which birds (10) are kept and which has a topography with low time variation, and the method comprises a step of counting incidents of temporary local disturbance of the topography of the target area.
The present invention provides canine antibodies that bind to canine interleukin-13 (canine IL-13) that have a high binding affinity for canine IL-13 and that can block the binding of canine IL-13 to the canine Type II heterodimer IL-4 receptor. The present invention also provides methods of using the antibodies of the present invention in the treatment of atopic dermatitis in dogs.
A61P 37/00 - Drugs for immunological or allergic disorders
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
alpha alpha (canine IL-4Rα or cIL-4Rα) of the canine Type II heterodimer IL-4 receptor. The present invention also provides methods of using the antibodies of the present invention in the treatment of atopic dermatitis in dogs.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
The present invention provides a vaccine for rabies virus and methods of making and using the vaccine alone, or in combinations with other protective agents.
A system for opening ampoules, the system comprising a beam comprising at least one opening for receiving part of an ampoule and an ampoule carrier for holding one or more ampoules. The system is configured to rotate the beam relative to the carrier, such that the rotation causes opposite sides of said opening to apply pressure to said received ampoule held by the carrier, to thereby break off said part of the ampoule received by the opening.
B65B 3/00 - Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans or jars
40.
Process for Preparing Large Size Isoxazoline Particles
An improved process to produce large isoxazoline compound particles which comprises initiating crystallization and then maintaining the temperature of the crystallization in the metastable region by removing, reheating and recycling a portion of the solvent thereby allowing the existing crystals to grow larger while minimizing the formation of newer smaller crystals.
C07D 261/04 - Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
A01N 43/80 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms, as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,2
41.
ISOXAZOLINE COMPOSITIONS AND THEIR USE AS ANTIPARASITICS
This invention relates to methods for controlling parasitic infestations of animals and their environments, and, more particularly, to methods using isoxazolines to control parasites in or on animals or in their environments, as well as treat parasitoses of animals. The isoxazolines include 4-(isoxazolinyl)-benzamides (specifically, substituted 4-(5-(halomethyl)-5-phenyl-isoxazolin-3-yl)-benzamides) and 4-(isoxazolinyl)-benzothioamides (specifically, substituted 4-(5-(halomethyl)-5-phenyl-isoxazolin-3-yl)-benzothioamides). This invention also relates to compositions comprising the isoxazolines for use in such methods, the use of the isoxazolines to make medicaments for use in such methods, and kits comprising the isoxazolines for carrying out such methods. This invention further relates to the use of the isoxazolines as medicaments, particularly medicaments that can be used in the above-referenced method.
C07D 261/04 - Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
A01N 43/80 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms, as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,2
A01N 47/12 - Carbamic acid derivatives, i.e. containing the group —O—CO—NThio-analogues thereof containing a —O—CO—N group, or a thio-analogue thereof, neither directly attached to a ring nor the nitrogen atom being a member of a heterocyclic ring
A01N 47/18 - Carbamic acid derivatives, i.e. containing the group —O—CO—NThio-analogues thereof containing a —O—CO—N group, or a thio-analogue thereof, directly attached to a heterocyclic or cycloaliphatic ring
A01N 53/00 - Biocides, pest repellants or attractants, or plant growth regulators containing cyclopropane carboxylic acids or derivatives thereof
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
42.
A VACCINE FOR PROTECTION AGAINST STREPTOCOCCUS SUIS SEROTYPE 9, SEQUENCE TYPE 16
The present invention pertains to a vaccine comprising in combination an IgM protease antigen of Streptococcus suis and a Streptococcus suis bacterin of serotype (9), sequence type (16), for use in a method for protecting pigs against a pathogenic infection with Streptococcus suis serotype (9), sequence type (16).
The present invention relates to a vaccine for use in a method of inducing an immune response in a canine against infectious canine hepatitis and/or infectious tracheobronchitis. To combine a convenient way of administering the vaccine and a good protection against ICH and infectious tracheobronchitis, the vaccine is a first vaccine comprising a canine adenovirus type 2, and the method comprises - administration of an immunologically effective dose of the first vaccine, - subcutaneous administration of an immunologically effective dose of a second vaccine comprising a canine adenovirus type 2 7-42 days after the first vaccine, and - oral administration of an immunologically effective dose of a third vaccine comprising a canine adenovirus type 2 10-14 months after the first vaccine.
C07D 215/233 - Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
C07C 69/67 - Esters of carboxylic acids having esterified carboxyl groups bound to acyclic carbon atoms and having any of the groups OH, O-metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
48.
PROCESSES FOR MAKING ENDOCHIN-LIKE QUINOLONES FROM ALKYL 3-(3-ALKOXYPHENYL)AMINO)-2-(4-(4-ALKOXY)PHENOXY)PHENYL)BUT-2-ENOATE
C07C 225/16 - Compounds containing amino groups and doubly-bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly-bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
The present invention provides a vaccine for canine Lyme disease and methods of making and using the vaccine alone, or in combinations with other protective agents.
05 - Pharmaceutical, veterinary and sanitary products
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
veterinary preparations for the prevention and treatment of dermatological disorders for companion animals providing a web site featuring veterinary information, provision of veterinary information
The present invention discloses novel recombinant multivalent non-pathogenic Marek's Disease virus constructs that encode and express both Infectious Laryngotracheitis Virus protein antigens and an Infectious Bursal Disease virus protein antigen, and methods of their use in poultry vaccines.
This invention is directed to a pharmaceutical composition for drinking water administration comprising isoxazoline compounds of formula (I) and a polysorbate surfactant and diethylene glycol monoethyl ether (transcutol); and the use of the composition to treat or prevent parasite infestations of animals.
A61K 9/00 - Medicinal preparations characterised by special physical form
A01N 25/02 - Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of applicationSubstances for reducing the noxious effect of the active ingredients to organisms other than pests containing liquids as carriers, diluents or solvents
A01N 43/80 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms, as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,2
The present invention pertains to the use of conjugated fumonisin (FUM) in a method to protect an animal against FUM induced mycotoxicosis, in particular to protect against a decrease in average daily weight gain, intestinal damage, liver damage and kidney damage as a result of the ingestion of FUM.
The present invention discloses antibodies to canine PD-I that have specific sequences and a high binding affinity for canine PD-I. The invention also discloses the use of the antibodies of the present invention in the treatment of cancer in dogs.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A method for external fish parasite monitoring in aquaculture, comprising the steps of:
submerging a camera (52) in a sea pen containing fish, the camera having a field of view;
capturing images of the fish with the camera (52); and
identifying external fish parasite on the fish by analyzing the captured images, characterized in that
a target region within the field of view of the camera (52) is illuminated from above and below with light of different intensities and/or spectral compositions.
The present invention regards recombinant HVT (rHVT) constructs, useful as multivalent vector vaccine for poultry. The rHVT comprise 4 heterologous genes from poultry pathogens: the VP2 gene from IBDV, the F gene from NDV, and the gD and gI genes from ILTV. The VP2 and F genes are inserted in the Us genome region of the rHVT. The gD-gI genes are inserted in the UL genome region, either between UL44 and UL45, or between UL45 and UL46. The rHVTs proved to be genetically stable in vitro and in vivo, and expressed all inserted genes well enough to induce protective immunity in vaccinated poultry against IBDV, NDV, and ILTV.
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A system for external fish parasites monitoring in aquaculture, the system comprising:
a camera (52) suitable to be submerged in a sea pen suitable for containing comprising fish, the camera being arranged for capturing images of the fish; and
an electronic image processing system (86) configured for identifying external fish parasites on the fish by analyzing the captured images,
wherein:
a ranging detector (54) configured for detecting the presence of fish and measuring a distance from the detector to the fish is mounted adjacent to the camera (52); and
an electronic control system (12) is arranged to control a focus of the camera (52) on the basis of the measured distance and to trigger the camera (52) when a fish has been detected within a predetermined distance range.
A Process for the Preparation of N-(bis(4-methoxyphenyl)methyl)-6-oxo-2-(pyridazin-3-yl)-1,6-dihydropyrimidine-5-carboxamide with improved reaction conditions and reduced use of toxic reagents and solvents.
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 237/24 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
C07C 213/02 - Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions involving the formation of amino groups from compounds containing hydroxy groups or etherified or esterified hydroxy groups
C07C 213/08 - Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions not involving the formation of amino groups, hydroxy groups or etherified or esterified hydroxy groups
The invention relates to a diagnostic use of an African Swine Fever Vims CD2v protein, a method, a device, and a kit for the detection of the presence of ASFV antibodies in a test sample, in particular the use thereof in a DIVA immunoassay.
The invention pertains to a vaccine comprising non-live antigen of a poultry pathogen and a mucoadhesive adjuvant, for use in boosting an immune response in a poultry animal directed against the poultry pathogen by administering the vaccine mucosally to the poultry animal. The invention also pertains to a vaccine comprising a liquid pharmaceutically acceptable carrier, a non-live antigen of a poultry pathogen and a mucoadhesive adjuvant, as well as a method of boosting an immune response in a poultry animal, which immune response is directed against a poultry pathogen, by administering a vaccine mucosally to the poultry animal, the vaccine comprising a non-live antigen of the said poultry pathogen and a mucoadhesive adjuvant.
The present invention relates to new anthelmintic compounds. These compounds can for example be used in the treatment of the kind of worm disease caused by helminths such as Dirofilaria, in particular Dirofilaria immitis.
C07D 213/71 - Sulfur atoms to which a second hetero atom is attached
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
The present invention relates to new anthelmintic compounds. These compounds can for example be used in the treatment of the kind of worm disease caused by helminths such as Dirofilaria, in particular Dirofilaria immitis.
Currently, there is no effective vaccination against M. bovis on the market, and treatment options become increasingly limited due to restrictions in the use of, and resistance to antibiotics. This is complicated by results that demonstrate the induction of vaccine-enhanced disease, upon the use of certain M. bovis proteins as a vaccine. Thus, there is an urgent need for an effective and safe M. bovis vaccine. A novel vaccine composition was found that comprises one or more recombinant proteins which (combined) contain one or more epitopes from each of a set of specific M. bovis proteins. Vaccines based on these recombinant proteins were found to be safe, and were effective in protecting ruminants against infection and disease resulting from a severe challenge infection with M. bovis, as was apparent from a strong reduction of lung damage and colonisation of the trachea.
C07K 14/30 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Mycoplasmatales, e.g. Pleuropneumonia-like organisms [PPLO]
The present invention pertains to the use of conjugated zearalenone (ZEA) in a method to protect an animal against ZEA induced mycotoxicosis, in particular to protect against decreased weight gain, kidney damage, liver damage and damage to a reproductive organ.
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
The present invention pertains to the use of conjugated T-2 toxin (T2) in a method to protect an animal against T2 induced mycotoxicosis, in particular to protect against a decrease in average daily weight gain, intestinal damage, skin damage and snout damage, thus one or more of these signs of mycotoxicosis induced by T2 as a result of the ingestion of T2.
A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
The present invention pertains to the use of conjugated aflatoxin (AFB) in a method to protect an animal against AFB induced mycotoxicosis, in particular to protect against a decrease in average daily weight gain, immune suppression, icterus, hemorrhagic enteritis as a result of the ingestion of AFB.
The present invention relates to vaccines against influenza virus infection or disease for targets with pre-existing antibodies against influenza virus HA head domain. The invention regards a recombinant vector expressing a HA stem polypeptide, a vaccine comprising the vector or a host cell with said vector, uses of the vector, the host cell, or the vaccine, and methods for reducing influenza virus infection or disease. The recombinant vector can be a nucleic acid such as a eukaryotic expression plasmid or an RNA, a virus, or a replicon particle (RP). This vaccination allows for the induction of an early- and effective immune-response against Influenza virus induced infection or disease, not hindered by pre-existing anti-HA head domain antibodies.
The present invention pertains to a vaccine comprising in combination non-replicating immunogen of porcine circo virus type 2 (PCV2), non-replicating immunogen of Mycoplasma hyopneumoniae and conjugated deoxynivalenol (DON) for protecting swine against an infection with porcine circo virus type 2, an infection with Mycoplasma hyopneumoniae and DON induced mycotoxicosis.
The present invention provides caninized rat antibodies to canine IL-31 receptor alpha that have a high binding affinity for canine EL-31 receptor alpha, and that can block the binding of canine IL-31 to canine EL-31 receptor alpha. The present invention further provides the use of the antibodies for the treatment of atopic dermatitis in dogs.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
The subject invention is the novel use of an injectable pharmaceutical composition comprising tildipirosin for the treatment and prophylaxis of foot rot. The use of a single subcutaneous dose of tildipirosin has been demonstrated to effectively treat naturally occurring foot rot.
A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
A61K 9/00 - Medicinal preparations characterised by special physical form
The present invention provides recombinant vectors encoding a chimeric coronavirus spike protein. The present invention further provides new immunogenic compositions and vaccines comprising these recombinant vectors. Methods of administering these immunogenic compositions and vaccines to animal subjects, including humans, felines, and avians, to protect them against coronaviruses also are included. Methods of making the immunogenic compositions and vaccines alone or in combinations with other protective agents are provided too.
The invention relates to a live attenuated parvovirus for use in the protection of an animal against parvovirus infection, wherein the live attenuated parvovirus is administered to the animal as a single dose and is administered during weeks 2-10 of age of the animal. The invention further relates to vaccines comprising the live attenuated parvovirus as well as methods for their production.
The invention concerns a baculovirus expression vector for recombinantly expressing an FMDV capsid precursor protein under control of a promoter, the expression vector comprising a nucleic acid sequence encoding the FMDV capsid precursor protein and the translational enhancers Syn2 land p10UTR. The invention further relates to a host cell comprising the baculovirus expression vector, a method of producing FMDV virus-like particles (VLPs), and a method of producing a vaccine.
The present invention pertains to a vaccine comprising an immunologically effective amount of an IgM protease antigen of Streptococcus suis, for use in a method for protecting pigs against a pathogenic infection with Streptococcus suis by administering the vaccine only once, wherein the vaccine comprises at most 120 μg per dose of the antigen.
The present invention provides caninized rat antibodies to canine IL-31 receptor alpha that have a high binding affinity for canine IL-31 receptor alpha, and that can block the binding of canine IL-31 to canine IL-31 receptor alpha. The present invention further provides the use of the antibodies for the treatment of atopic dermatitis in dogs.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
A buccal administration method of flunixin has been developed now to provide an easy to use and effective method of reducing pain in livestock animals (e.g. swine, cattle, sheep, goats, etc.).
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
90.
METHOD FOR AUTOMATIC SEA LICE MONITORING IN SALMON AQUACULTURE
The present invention pertains to a method for automatic sea lice monitoring in fish aquaculture, the method comprising submerging a camera (4) in a sea pen (300) comprising fish, using the camera to make an image of at least one of said fish, analysing the image to differentiate between individual sea lice present on the fish and the fish itself and assessing the number of sea lice present on the fish, wherein the camera is attached to a device (1, 10, 100) for guiding the salmon along an imaging track (5), the camera being directed to the track.
The present invention regards a new recombinant HVT (rHVT) construct, useful as multivalent vector vaccine for poultry. The rHVT comprises 4 heterologous genes from poultry pathogens: the VP2 gene from IBDV, the F gene from NDV, and the gD and gI genes from ILTV. The VP2 and F genes are inserted in the Us genome region of the rHVT. The gD-gI genes are inserted in the UL genome region, between the UL54 and the LORF3 genes. The new rHVT-VP2-F-gD-gI proved to be genetically stable in vitro and in vivo, and expressed all inserted genes well. Also it was an effective vaccine against severe challenge infections with NDV, IBDV, and ILTV.
The present invention provides new vaccines for felines and ferrets to aid in reducing shedding of severe acute respiratory syndrome coronavirus 2 by infected felines or ferrets. Methods of making and using the vaccines alone or in combinations with other protective agents are also provided.
The present invention relates to a novel equine parvovirus associated with respiratory distress and recurrent laryngeal neuropathy in equine, to nucleic acid fragments and proteins of the virus and to vaccines based upon the virus, proteins and nucleic acid fragments. The invention also relates to a diagnostic test for the detection of the vims or antibodies against the virus.
C07K 14/015 - Parvoviridae, e.g. feline panleukopenia virus, human parvovirus
C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
A61K 39/23 - Parvoviridae, e.g. feline panleukopenia virus
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
95.
A COMBINATION OF VACCINES TO PROPHYLACTICALLY TREAT A PIG
The invention pertains to a combination of a first vaccine comprising anon-replicating immunogen of porcine circovirus type 2 (PCV-2) and a non-replicating immunogen of Mycoplasma hyopneumoniae, and a second vaccine comprising a live attenuated porcine reproductive and respiratory syndrome (PRRS) virus, for use in prophylactically treating a pig against an infection with PCV-2, an infection with Mycoplasma hyopneumoniae and an infection with PRRS virus, by associated separate injection of the first vaccine and the second vaccine into a tissue of the pig at a first and a second injection site respectively, wherein the first and second injection sites are at most 5 cm apart from each other.
A solid oral pharmaceutical composition for delivery of a pharmaceutically acceptable active ingredient to an animal where the composition comprises an isoxazoline compound, a solvent and an excipient, a process for the manufacture of such solid oral pharmaceutical composition and a method of controlling a parasite infection administering such solid oral pharmaceutical composition.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
A61K 31/422 - Oxazoles not condensed and containing further heterocyclic rings
A61K 47/16 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
A61P 43/00 - Drugs for specific purposes, not provided for in groups
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61K 31/35 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
The present invention relates to injectable compositions comprising the combination of an isoxazoline compound as well as a physiologically active macrocyclic lactone such as moxidectin.
The present invention provides compositions for treating canine atopic dermatitis that comprise a fusion protein that binds canine IL-22, a caninized anti-pruritic antibody, and a caninized anti-inflammatory antibody. The present invention further provides compositions that comprise a bispecific binding partners that comprises that fusion protein and a caninized anti-pruritic antibody or a caninized anti-inflammatory antibody, or alternatively, a bispecific antibody comprising a caninized anti-pruritic antibody and a caninized anti-inflammatory antibody, which in addition comprises a fusion protein that binds canine IL-22.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61P 37/00 - Drugs for immunological or allergic disorders
100.
SWINE INFLUENZA A VIRUS VACCINE COMPRISING TWO DISTINCT RNA REPLICON PARTICLES
The present invention relates to an immunogenic composition comprising first and second RNA replicon particles. The first RNA replicon particle comprises a nucleic acid construct comprising first and second nucleic acid sequences encoding first and second hemagglutinin (HA) antigens of a Swine influenza A virus (IAV-S). The first HA antigen is a of the A/swine/Gent/1/1984-like H3N2 (Gent/84) lineage, and the second HA antigen is of the A(H1N1)pdm09 (pdm09) lineage. The second RNA replicon particle comprises a nucleic acid construct comprising third and fourth nucleic acid sequences encoding third and fourth HA antigens of S. The third HA antigen is of the A/swine/Scotland/410440/1994-like H1huN2 (Scot/94) lineage, and the fourth HA antigen is of the Eurasian avian-like H1avN1 (EA) lineage. In other embodiments, the present invention relates to a vaccine, which may be used against influenza A virus infection, and comprising the immunogenic composition. Further provided are methods of making the vaccine and use of the vaccine.
